Stryker Corporation (SYK) Shares Sold by Atlantic Trust LLC
Atlantic Trust LLC lessened its position in Stryker Corporation (NYSE:SYK) by 37.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 900 shares of the medical technology company’s stock after selling 550 shares during the quarter. Atlantic Trust LLC’s holdings in Stryker were worth $128,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Acrospire Investment Management LLC purchased a new position in shares of Stryker in the 2nd quarter valued at approximately $111,000. Motco lifted its stake in shares of Stryker by 50.7% in the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock valued at $115,000 after purchasing an additional 278 shares during the period. San Francisco Sentry Investment Group CA lifted its stake in shares of Stryker by 47.8% in the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock valued at $143,000 after purchasing an additional 325 shares during the period. Bruderman Asset Management LLC purchased a new position in shares of Stryker in the 2nd quarter valued at approximately $150,000. Finally, James Investment Research Inc. purchased a new position in shares of Stryker in the 2nd quarter valued at approximately $155,000. Institutional investors own 74.97% of the company’s stock.
Stryker Corporation (NYSE:SYK) traded down $0.36 during trading on Thursday, hitting $153.31. The company’s stock had a trading volume of 1,358,800 shares, compared to its average volume of 1,177,760. The company has a market cap of $57,509.09, a price-to-earnings ratio of 24.35, a price-to-earnings-growth ratio of 2.42 and a beta of 0.78. Stryker Corporation has a twelve month low of $116.27 and a twelve month high of $160.62. The company has a current ratio of 2.37, a quick ratio of 1.61 and a debt-to-equity ratio of 0.63.
Stryker (NYSE:SYK) last posted its earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.02. The business had revenue of $3.01 billion during the quarter, compared to analyst estimates of $2.97 billion. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The company’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.39 EPS. research analysts expect that Stryker Corporation will post 6.47 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 31st. Shareholders of record on Friday, December 29th will be issued a $0.47 dividend. This is a positive change from Stryker’s previous quarterly dividend of $0.43. The ex-dividend date is Thursday, December 28th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.23%. Stryker’s dividend payout ratio (DPR) is presently 36.32%.
In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of Stryker stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $155.34, for a total value of $776,700.00. Following the completion of the sale, the insider now owns 83,207 shares of the company’s stock, valued at approximately $12,925,375.38. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 7.40% of the stock is currently owned by company insiders.
A number of brokerages have issued reports on SYK. BMO Capital Markets upgraded Stryker to a “market perform” rating and set a $163.00 price objective for the company in a research note on Tuesday. Needham & Company LLC reiterated a “hold” rating on shares of Stryker in a research note on Thursday, December 7th. ValuEngine cut Stryker from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Robert W. Baird upgraded Stryker from a “neutral” rating to an “outperform” rating in a research note on Friday, November 24th. Finally, SunTrust Banks reiterated a “buy” rating and set a $161.00 price objective on shares of Stryker in a research note on Friday, November 17th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $153.19.
ILLEGAL ACTIVITY NOTICE: “Stryker Corporation (SYK) Shares Sold by Atlantic Trust LLC” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/stryker-corporation-syk-shares-sold-by-atlantic-trust-llc/1763868.html.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with Analyst Ratings Network's FREE daily email newsletter.